Cardiovascular Referral Tightened Risk Factor Control in Prostate Cancer, but Event Reduction Remained Elusive
Men treated for prostate cancer often carry a substantial burden of cardiovascular risk, and many arrive in oncology clinics with blood pressure, lipids, smoking, and exercise habits already working against them. The question tested here was straightforward and clinically important: would routing patients to a cardiovascular specialist and applying a structured prevention plan improve outcomes beyond usual care?
The answer was mixed. The intervention improved risk factor control, especially cholesterol, yet it did not translate into a measurable reduction in major cardiovascular events over follow-up.
Trial Design and the Prevention Strategy Tested at Scale
This randomized clinical trial enrolled patients with prostate cancer from 55 sites in 8 countries between 2015 and 2025. Eligibility was limited to men diagnosed with prostate cancer within the prior 12 months, those who had started androgen deprivation therapy, or those scheduled to begin it within a month. The trial population therefore centered on a group exposed to a treatment environment already known to worsen cardiometabolic risk.
A total of 2487 patients were analyzed, with a mean age of 68 years. Participants were assigned in a 1:1 ratio to usual care alone or usual care plus routine referral to an internist or cardiologist. The specialty intervention was not a casual consult. It used a prespecified prevention package that targeted systolic blood pressure of 130 mm Hg or lower, recommended a statin regardless of baseline cholesterol, encouraged smoking cessation, and included advice on diet and physical activity.
The statin component deserves emphasis because it was deliberately nonselective. Rather than waiting for cholesterol thresholds to trigger therapy, the protocol pushed lipid-lowering treatment broadly as part of cardiovascular prevention in a cancer population with elevated baseline risk. In practice, that kind of approach tests whether risk reduction can be standardized instead of left to fragmented primary care follow-up.
Cholesterol Fell, and Statin Uptake Explains Much of the Difference
Over a median follow-up of 5.8 years, the trial showed a win ratio of 1.60 in favor of the intervention arm, with a 95% confidence interval of 1.42 to 1.81. The clearest driver of that advantage was cholesterol control. Mean cholesterol was 12 mg/dL lower in the intervention group, with a 95% confidence interval of 9 to 15 mg/dL, and that effect tracked closely with greater protocol-mandated statin use.
The clinical meaning is direct: when men with prostate cancer were connected to cardiovascular specialists, lipid management became more consistent and more aggressive. In oncology settings where chronic risk factor treatment may be fragmented, this kind of referral pathway can change prescribing behavior quickly.
A brief sentence captures the central signal: cholesterol improved because statins were used more often and more systematically.
Blood pressure moved less dramatically. Mean close-out systolic blood pressure was 131.1 mm Hg in the intervention group and 132.9 mm Hg in the control group. Those values sit close to the trial target, but the between-group difference was modest. The blood pressure finding matters because it suggests the intervention succeeded more convincingly in one prevention domain than in another, even though both were targeted in the protocol.
Major Cardiovascular Events Did Not Separate
Despite the improvement in risk factor control, there was no difference in the time to cardiovascular death, myocardial infarction, stroke, or heart failure between groups. The subdistribution hazard ratio was 1.08, with a 95% confidence interval of 0.79 to 1.49.
This is the part of the trial that keeps the interpretation grounded. Better cholesterol numbers are clinically relevant, but they did not produce a measurable reduction in hard cardiovascular outcomes within the follow-up available here. For clinicians, that means the intervention proved capable of changing treatment patterns and intermediate markers, but not yet capable of demonstrating fewer events in this population.
The result is not a failure of prevention so much as a reminder that endpoint selection changes the story. Lipid control can improve faster than event curves move, particularly in patients with competing oncologic risks and a long enough time horizon for atherosclerotic benefit to emerge unevenly.
What the Findings Mean for Oncology and Cardiology Practice
The trial supports a practical message for prostate cancer care teams: cardiovascular prevention should not be treated as an afterthought once androgen deprivation therapy begins. Men starting ADT already face a risk profile that can worsen with treatment, and this study shows that proactive referral can improve management of modifiable factors, especially cholesterol.
The specialist model also has operational implications. It places responsibility for prevention in a setting where statin prescribing, blood pressure targets, smoking cessation counseling, and exercise guidance are handled with more consistency than is often possible during busy oncology visits. For patients, that may mean one more appointment; for systems of care, it may mean a more reliable way to close a well-known gap.
Still, event prevention remains unproven in this trial. The absence of a difference in cardiovascular death, myocardial infarction, stroke, or heart failure leaves open several possibilities: the follow-up may have been insufficient to capture downstream benefit, the absolute event rate may have been too low, or the magnitude of risk factor improvement may have been too small to shift clinical endpoints over the observed period.
The Clinical Question That Remains
This trial establishes that routine referral can improve cholesterol control in men with prostate cancer. It does not establish that the strategy lowers major cardiovascular events.
For now, the most defensible conclusion is narrower than the intervention itself: systematic cardiovascular co-management changes treatment quality, but the path from better risk factor numbers to fewer myocardial infarctions, strokes, and cardiovascular deaths still needs direct confirmation in this population. The next step is not more enthusiasm; it is clearer evidence that the improved intermediate outcomes can be converted into fewer clinical events over time.